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The ubiquitously expressed G-proteins G12 and G13
whose function is currently not clear have been shown
to be activated in platelet membranes through receptors
that stimulate platelet aggregation. We used intact hu-
man platelets to determine whether a subunits of both
G-proteins can be phosphorylated under physiological
conditions. Activation of human platelets by thrombin
and the thromboxane A2 receptor agonist U46619 lead to
phosphorylation of Ga12 and Ga13. Phosphorylation oc-
curred rapidly after addition of thrombin and was not
mediated by glycoprotein IIb/IIIa (integrin aIIbb3) acti-
vation. Phosphorylation of Ga12 and Ga13 could be mim-
icked by phorbol 12-myristate 13-acetate, and thrombin-
induced phosphorylation was inhibited by the protein
kinase C inhibitor calphostin C indicating an involve-
ment of protein kinase C in Ga12/13 phosphorylation in-
duced by thrombin in human platelets. The phosphoryl-
ation of both G protein a subunits was reconstituted in
COS-7 cells cotransfected with Ga12 or Ga13 and differ-
ent protein kinase C isoforms. Among the protein knase
C isoforms tested, protein kinase C b, d, and e were most
effective in promoting phosphorylation of Ga12 and Ga13
in a phorbol 12-myristate 13-acetate-dependent manner.
These data demonstrate that Ga12 and Ga13 are phos-
phorylated under in vivo conditions and that this phos-
phorylation involves protein kinase C.
G-proteins1 are heterotrimeric proteins which functionally
couple a variety of receptors to effectors that include adenylyl
cyclase, phospholipase C-b, cyclic GMP phosphodiesterase, and
various ion channels (1–4). Heterotrimeric G-proteins consist
of an a-subunit which binds and hydrolyzes GTP, a b- and a
g-subunit. The identity of the G-protein a-subunit defines the
heterotrimeric G-protein. Based on sequence and functional
homologies the a-subunits can be divided into four families
(Gas, Gai/o, Gaq, and Ga12) (5). In a given cell, several signal
transduction pathways involving different heterotrimeric G-
proteins operate in parallel, and there is increasing evidence
that the G-protein mediated signal transduction system under-
goes adaptation and cross-regulation at many different levels.
Protein phosphorylation and dephosphorylation is an impor-
tant regulatory mechanism found in a variety of signal trans-
duction systems. Several reports have shown that the a-sub-
units of some members of the Gi/o family can be phosphorylated
in vivo and in vitro. In platelets, thrombin, thromboxane A2
analogs, and phorbol esters lead to a protein kinase C mediated
phosphorylation of Gaz (6, 7). Furthermore, this phosphoryla-
tion blocks interaction of Gaz with Gbg (8). In addition, several
reports have shown that Gai can be phosphorylated in various
systems under conditions leading to protein kinase C and
cGMP dependent protein kinase activation (9–12). Most of
these reports suggest that Gai phosphorylation correlates with
inactivation of signaling via this G-protein (9, 11, 12).
The G-proteins G12 and G13 are ubiquitously expressed and
together constitute the G12 family (13). Studies using constitu-
tively activated forms of both a-subunits have provided evi-
dence that G12 and G13 are involved in the regulation of differ-
ent downstream effectors and signaling pathways, e.g. the Na1/
H1exchanger (14–16), the Jun-kinase/stress-activated protein
kinase pathway (17) and the Rho-dependent formation of stress
fibers (18). However, the effectors directly regulated by G12 and
G13 are currently unknown. It is clear that both G-proteins are
distinct frommost other G-proteins with regard to the biochem-
ical properties of their a-subunits. The receptor-catalyzed gua-
nine nucleotide exchange rate of G12 and G13 is very low when
measured in membrane fractions (19), and purified Ga12 and
Ga13 exhibit very slow rates of GDP dissociation and GTP
association (20, 21).
Platelets are a well described model system for studies of
G-protein mediated signal transduction processes. In human
platelet membranes both, Ga12 and Ga13, have been shown to
be activated through thrombin and thromboxane A2 receptors
(19). We therefore chose intact human platelets to test whether
Ga12 and Ga13 can be phosphorylated under in vivo conditions.
Our data show that treatment of human platelets with physi-
ological platelet activators leads to a rapid and sustained phos-
phorylation of both G-protein a-subunits and that this phos-
phorylation is mediated by protein kinase C.
EXPERIMENTAL PROCEDURES
Materials—Thrombin, thrombin receptor peptide (SFLLRNPND-
KYEPF), U46619, phorbol 12-myristate 13-acetate (PMA), protein A-
Sepharose, and Arg-Gly-Asp-Ser (RGDS) were from Sigma. Calphostin
C was from Calbiochem (San Diego, CA) and [32P]orthophosphate was
from DuPont NEN. Anti-Ga12 and -Ga13 antisera were raised against
peptides representing the carboxyl-terminal 10 amino acids of Ga12 and
Ga13, respectively. The cDNAs of Ga12 and Ga13 were carried by the
cytomegalovirus promotor containing vector pCIS. A b-galactosidase
construct inserted into pCIS was used as a transfection control. The
PKCa, bI, d, e, and z cDNAs were in the expression vector pMT2, and
the cDNA of PKCh was carried by pKSI (22).
Isolation of Platelets—Venous blood was collected from healthy drug-
free volunteers and anticoagulated with 6 mM citric acid, 12 mM sodium
citrate. Platelet isolation was carried out at room temperature. Platelet
rich plasma was prepared by centrifugation of whole blood for 20 min at
200 3 g. Platelet rich plasma was adjusted with citrate buffer to pH 6.5
and centrifuged two times at 200 3 g for 15 min to remove contami-
nating cells. Thereafter, platelets were pelleted by centrifugation for 10
min at 700 3 g and washed once in buffer A containing 138 mM NaCl,
6 mM KCl, 1 mM MgCl2, 5 mM NaHCO3, 5.5 mM glucose, 0.5 mM EDTA,
0.1% (w/v) bovine serum albumin, 0.5 unit/ml apyrase, and 20 mM
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Hepes (pH 7.4). Platelets were metabolically labeled by incubation in
the above buffer containing 1 mCi/ml [32P]orthophosphate for 2 h at
room temperature.
Immunoprecipitation—Metabolically labeled platelets were washed
once in buffer A (see above) and about 2 3 109 platelets were preincu-
bated for 3 min at 37 °C in 200 ml of the same buffer devoid of apyrase
and containing 1 mM CaCl2. Incubation was initiated by addition of
indicated agents (10 ml) and was stopped by adding 50 ml of 5% (w/v)
sodium dodecyl sulfate, 20 mM EDTA, 50 mM NaF, 50 mM Na4P2O7.
After 10 min at room temperature, 1 ml of precipitating buffer (1% (v/v)
Nonidet P-40, 1% (w/v) desoxycholate, 0.5% (w/v) sodium dodecyl sul-
fate, 150 mM NaCl, 1 mM dithiothreitol, 1 mM EDTA, 10 mM NaF, 5 mM
Na4P2O7, 0.2 mM phenylmethylsulfonyl fluoride, 10 mg/ml aprotinin,
and 10 mM TriszHCl (pH 7.4)) was added, and lysates were centrifuged
for 10 min at 12000 3 g. Thereafter, supernatants were precleared by
incubation with 50 ml of 12.5% (w/v) protein A-Sepharose beads for 1 h
at 4 °C at constant rotation. Sepharose beads were pelleted and super-
natants were incubated for another 1–1.5 h in the presence of 10 ml
antiserum. After addition of 50 ml of 12.5% (w/v) protein A-Sepharose
beads samples were incubated for 1 h at 4 °C, and immunocomplexes
were washed and prepared for SDS-PAGE as described (19).
Expression and Phosphorylation of Ga12 and Ga13 in COS-7 Cells—
COS-7 cells were cultured as described (23). For transfection experi-
ments, cells were seeded in 12-well plates at a density of 1 3 105 cells
per well and grown overnight. Cells were then washed with phosphate-
buffered saline solution and 1 mg of plasmid DNA mixed with 5 ml of
LipofectAMINE (Life Technologies, Inc.) in 0.5 ml of Opti-MEM was
added to each well. In control experiments, the total amount of DNA
was maintained constant by adding DNA from a vector encoding b-ga-
lactosidase. After 5 h, 0.5 ml of DMEM containing 20% (v/v) fetal bovine
serum was added, and cells were used for experiments about 45 h later.
For metabolic labeling, cells were washed 3 times with DMEM devoid of
phosphate. Thereafter cells were incubated for 2 h in 0.4 ml phosphate-
free DMEM containing 0.5 mCi/ml [32P]orthophosphate and 20 mM
HepeszNaOH (pH 7.4). Cells were then washed once with phosphate-
free DMEM and incubated in the absence or presence of the indicated
agents at 37 °C. Reactions were stopped by removing incubation me-
dium and adding of 100 ml of 1% (w/v) sodium dodecyl sulfate, 5 mM
EDTA, 20 mM NaF, 10 mM Na4P2O7. Immunoprecipitation of proteins
was done as described above.
Determination of Protein Kinase C Activity—Transfected COS-7
cells were washed twice with phosphate-buffered saline. Phosphoryl-
ation was initiated by adding 0.5 ml of permeabilization solution
consisting of 115 mM KCl, 15 mM NaCl, 0.5 mM MgCl2, 20 mM
HepeszNaOH (pH 7), 1 mM EGTA, 100 mM [g-32P]ATP (100 mCi/
mmol), 50 mM each of PKC substrate peptides A and B, 20 mM digi-
tonin, and 0.72 mM CaCl2 (to give a free Ca
21 concentration of 500 nM)
(24). Cells were incubated in the absence or presence of 100 nM PMA
for 10 min at 37 °C. 400 ml of the supernatant were then spotted onto
phosphocellulose paper (Whatman P81) and dried. Filter papers were
washed five times in 30% (v/v) acetic acid and counted. PKC substrate
peptides A and B represent the pseudosubstrate sites of PKCz (IYR-
RGSRRLRKL) and PKCd (MNRRGSIKQAKI) except for the substi-
tution of serine in place of alanine.
RESULTS
Human platelets metabolically labeled with [32P]orthophos-
phate were incubated with different agents which lead to the
inhibition or activation of platelet function, platelet lysates
were prepared, and Ga12 and Ga13 were then immunoprecipi-
tated from the lysates with specific antisera. No radioactive
phosphate was found in Ga12 and Ga13 immunoprecipitated
from untreated platelets or platelets incubated in the presence
of the PGI2 receptor agonist cicaprost, forskolin, or sodium
nitroprusside (data not shown). However, treatment of plate-
lets with the platelet activators thrombin and thromboxane A2
analogue U46619 as well as with the phorbol ester PMA re-
sulted in a marked phosphorylation of Ga12 and Ga13 (Fig. 1).
Thombin receptor peptide mimicked the effect of thrombin,
demonstrating the specific activation of the G-protein coupled
thrombin receptor. The extent of phosphorylation induced by
U46619 and thrombin receptor peptide was lower than that
promoted by PMA and thrombin. To confirm the specificity of
the antisera used for immunoprecipitation, the anti-Ga12 and
anti-Ga13 antisera were preincubated with the individual pep-
tides against which they were raised. Fig. 2 shows that immu-
noprecipitation of phosphorylated 42-kDa proteins by anti-
Ga12 and anti-Ga13 antisera was blocked by the respective
peptides. There was no cross-reactivity between both antisera
as the Ga12 peptide was unable to block precipitation by the
Ga13 antiserum and the Ga13 peptide had no effect on the
precipitation by the Ga12 antiserum. No phosphorylated pro-
tein was precipitated by preimmune sera (Fig. 2). Similarly and
in agreement with previous studies (7), immunoprecipitation
with an antiserum recognizing the C terminus of Gaq/11 did not
precipitate any phosphorylated Gaq/11 from lysates of platelets
treated with different agents (data not shown).
Time course experiments revealed a rapid and sustained
phosphorylation of Ga12 and Ga13 in response to thrombin (Fig.
3). Phosphorylation of both proteins was maximal 10 s after
addition of thrombin, whereas phosphorylation in response to
PMA was maximal not earlier than 2 min after PMA was
added. To rule out that phosphorylation of both proteins was
dependent on activation of glycoprotein IIb/IIIa (integrin
aIIbb3) we incubated platelets with the peptide RGDS prior to
addition of thrombin (Fig. 4). Pretreatment of platelets with
RGDS, an inhibitor of aIIbb3-fibrinogen binding, had no effect
on the thrombin induced phosphorylation of Ga12 and Ga13,
whereas it prevented formation of a platelet aggregate which
was usually visible about 3–4 min after addition of thrombin.
Thus, thrombin induced Ga12 and Ga13 phosphorylation is an
event occurring early during platelet activation.
Since the effect of thrombin was mimicked by the protein
kinase C activating phorbol ester PMA and since platelet acti-
vation is known to involve activation of protein kinase C (25–
27), we investigated the role of PKC in Ga12 and Ga13 phos-
phorylation. Fig. 4 shows that the effects of thrombin and PMA,
both employed at maximally effective concentrations were not
additive, suggesting that both agents acted through at least
similar mechanisms involving the phosphorylation of the same
residues. Calphostin C, a potent inhibitor of diacylglycerol and
Ca21-dependent isoforms of protein kinase C (28) inhibited the
effect of thrombin on the phosphorylation of Ga12 and Ga13 in
a concentration dependent manner in human platelets (Fig. 5),
indicating that protein kinase C is involved in the thrombin
dependent phosphorylation of Ga12 and Ga13.
To further elucidate the mechanism of Ga12/Ga13 phospho-
rylation and to study the possible involvement of specific pro-
tein kinase C isoforms, we tried to reconstitute the protein
kinase C dependent phosphorylation of both G-protein a-sub-
FIG. 1. Phosphorylation of Ga12 and Ga13 by different stimuli
in human platelets. Platelets were metabolically labeled with
[32P]H3PO4 and were subsequently incubated in the absence or pres-
ence of 3 mM U46619, 5 units/ml thrombin, 100 mM thrombin receptor
peptide (TRP) and 1 mM PMA at 37 °C for 3 min as described under
“Experimental Procedures.” Following solubilization of the platelets,
precipitates were prepared with an anti-Ga12 (left panel) and with an
anti-Ga13 antiserum (right panel). Shown are autoradiograms of SDS-
polyacrylamide gels which are representative of three experiments
conducted under identical conditions. The position of the 43-kDa stand-
ard protein is shown on the left of each panel.
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units in COS-7 cells. Fig. 6 shows that expression of different
protein kinase C isoforms in COS-7 cells resulted in increased
basal protein kinase C activity measured in permeabilized cells
using PKC substrate peptides. Incubation of cells with the
phorbol ester PMA increased the protein kinase C activity in
cells expressing the protein kinase C isoforms a, b, d, e, and h,
whereas the kinase activity in cells transfected with the atyp-
ical PKC isoform z was unresponsive to PMA. These data show
that protein kinase C isoforms expressed in COS-7 cells were
functionally active. We then coexpressed individual PKC iso-
forms and Ga12 or Ga13 and measured the phosphorylation of
both G-protein a-subunits in response to PMA (Fig. 7). In
metabolically labeled COS-7 cells transfected only with a con-
trol plasmid encoding b-galactosidase and incubated in the
presence of PMA, no phosphorylated Ga12 or Ga13 was immu-
noprecipitated, whereas in cells transfected with Ga12 or Ga13,
PMA induced the phosphorylation of both proteins presumably
through the activation of endogenous protein kinase C. This
PMA-induced phosphorylation of Ga12 as well as of Ga13 was
unchanged in cells coexpressing the PKC isoforms a and h,
indicating that these PKC isoforms were unable to mediate the
effect of PMA on phosphorylation of Ga12 and Ga13 in our
cotransfection system. However, in cells cotransfected with
PKCb, d, or e and Ga12 or Ga13 PMA-induced phosphorylation
of each G-protein a-subunit was increased compared to cells
FIG. 2. Specificity of antisera used for precipitation of Ga12
and Ga13 from human platelet lysates. Metabolically labeled plate-
lets were incubated in the absence (thrombin 2) or presence of 5
units/ml thrombin (thrombin 1) for 2 min. Platelets were solubilized,
and the indicated antisera were added (PIS, preimmune serum). Prior
to addition, the anti-Ga12 and the anti-Ga13 antiserum had been pre-
incubated overnight at 4 °C in the absence (peptide 2) or presence of 10
mg/ml of the indicated C-terminal decapeptides of Ga12 and Ga13
against which the antisera had been raised. Immunoprecipitation was
performed as described under “Experimental Procedures,” and precip-
itated proteins were subjected to SDS-PAGE. Shown are autoradio-
grams of SDS-polyacrylamide gels with the position of standard pro-
teins indicated on the left. These results represent one of two
experiments.
FIG. 3. Time courses of thrombin and PMA induced phospho-
rylation of Ga12 and Ga13 in human platelet. Labeled platelets
were incubated in the absence or presence of 5 units/ml thrombin
(thrombin 2/1, panels A and C) and 1 mM PMA (PMA 2/1, panels B and
D) for the indicated time periods, and platelets were solubilized. Pro-
teins were immunoprecipitated with the anti-Ga12 (panels A and B) or
the anti-Ga13 antiserum (panels C and D) as described. Precipitated
proteins were subjected to SDS-PAGE. Shown are autoradiograms of
SDS-polyacrylamide gels with the position of standard proteins indi-
cated on the left (kDa). These results represent one of two experiments.
FIG. 4. Lack of additivity of thrombin and PMA stimulated
Ga12/Ga13 phosphorylation and effect of RGDS on thrombin de-
pendent phosphorylation of Ga12 and Ga13 in human platelet.
Panels A and B, metabolically labeled platelets were incubated without
(2) or with 10 units/ml thrombin (T), 1 mM PMA (P) and 10 units/ml
thrombin 1 1 mM PMA (T1P) for 3 min. Panels C and D, platelets were
preincubated without or with 0.5 mM RGDS (RGDS 2/1) for 5 min.
Thereafter, 5 units/ml thrombin (thrombin 1) or vehicle (thrombin 2)
was added and platelets were incubated for 2 min at 37 °C. Solubilized
platelets were then incubated with the anti-Ga12 (panels A and C) or the
anti-Ga13 antiserum (panels B and D) as described. Precipitated pro-
teins were subjected to SDS-PAGE. Shown are autoradiograms of SDS-
polyacrylamide gels with the position of the 43-kDa standard protein
shown on the left.
FIG. 5. Effect of calphostin C on thrombin induced phospho-
rylation of Ga12 and Ga13 in human platelet. [
32P]H3PO4-labeled
platelets were preincubated without or with the indicated concentration
of calphostin C (calph. C) for 10 min. Thereafter, 5 units/ml thrombin
(thrombin 1) or vehicle (thrombin 2) was added, and platelets were
incubated for 2 min at 37 °C. Solubilized platelets were then incubated
with the anti-Ga12 (left panel) or the anti-Ga13 antiserum (right panel)
as described. Precipitated proteins were subjected to SDS-PAGE.
Shown are autoradiograms of SDS-polyacrylamide gels with the posi-
tion of the 43-kDa standard protein shown on the left. Samples loaded
on the left lane of each panel contained 0.2% (v/v) Me2SO during
preincubation and incubation with thrombin in order to rule out inhib-
itory effects of Me2SO, which was present at this concentration in
samples preincubated with 2 mM calphostin C.
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transfected only with the Ga-subunit. The amount of Ga12 and
Ga13 expressed in different cotransfected cells was the same
when tested by Western blotting of cell lysates (data not
shown). Quantification of radioactivity incorporated into Ga12
and Ga13 by using the PhosphorImager showed that PMA
stimulated phosphorylation about 4.5-fold in cells expressing
PKCb compared to control cells, whereas PMA stimulated
phosphorylation of Ga12 and Ga13 in cells cotransfected with
PKCd and e was slightly lower (2–3.5-fold). These data demon-
strate that the PKC-dependent phosphorylation of Ga12 and
Ga13 observed in human platelets can be reconstituted by co-
transfection of different PKC isoforms and both G-protein
a-subunits in COS-7 cells.
DISCUSSION
The object of this study was to test whether members of the
Ga12 family can be phosphorylated under physiological con-
ditions. Human platelets were used as an experimental sys-
tem since they contain both Ga12 and Ga13 as well as a
variety of well described signaling pathways. We demon-
strate that in human platelets both Ga12 and Ga13 undergo
phosphorylation in response to the platelet activators throm-
bin and thromboxane A2. Phosphorylation occurred inde-
pendent of glycoprotein IIb/IIIa (integrin aIIbb3) activation
and was maximal within seconds after addition of thrombin
to platelets, indicating that it is an event occurring during
the first phase of platelet activation. Phosphorylation of Ga12
and Ga13 could also be observed after addition of phorbol
ester PMA, and thrombin induced phosphorylation was
blocked by the protein kinase C inhibitor calphostin C,
strongly suggesting that phosphorylation of both G-proteins
involves protein kinase C. PKC activation can be observed
very early after activation of platelets by thrombin and is
thought to play an important role in agonist stimulated ac-
tivation of platelets (25–27). Several PKC isoforms have been
described in platelets including isoforms a, b, d, and z (25–27,
29, 30). It was demonstrated that thrombin induces a very
rapid rise in diacylglycerol levels followed by a sustained
translocation of PKCa, b, and z from the cytosolic to the
membrane fraction of platelets (24). Both the thrombin in-
duced diacylglycerol generation as well as the translocation
of PKC isoforms were independent of glycoprotein IIb/IIIa
activation (24). Thus, this rapid activation of PKC can well
account for the phosphorylation of Ga12 and Ga13 in platelets.
The PKC isoform b is a good candidate for mediating the
phosphorylation of Ga12 and Ga13 as seen in COS-7 cells
cotransfected with PKCb and Ga12 or Ga13, addition of PMA
led to a very efficient phosphorylation of both G-proteins
compared to control cells. It is, however, not clear whether
PKC directly phosphorylates Ga12 and Ga13 or whether phos-
phorylation occurs through another yet unknown process
involving PKC.
Ga12/13 phosphorylation in activated platelets bears some
resemblance to the phosphorylation of Gaz in platelets (6, 7).
Gaz was shown to be the substrate of PKC and the primary site
of phosphorylation has been mapped to Ser27 of Gaz whereas
Ser16 serves as a secondary site for PKC phosphorylation. Ser27
and Ser16 are situated in the N-terminal region of the a-sub-
unit which makes contact with Gbg (31), and biochemical evi-
dence has been provided that phosphorylation of Gaz by PKC
blocks interaction with Gbg (8). However, the physiological role
of Gaz and its phosphorylation remains obscure. In analogy to
Gaz we mutagenized Ser
31 of Ga13 which corresponds to Ser
16
in Gaz as well as Ser
39 of Ga13 which also lies in the domain
which is thought to contact Gbg. Both the single mutants as
well as the double mutant were, however, still phosphorylated
in response to phorbol esters when expressed in COS-7 cells
(data not shown), indicating that phosphorylation of Ga13 oc-
curs at different residues and that the functional consequences
of Ga13 phosphorylation are probably different from those of
Gaz phosphorylation.
G12 and G13 have been shown to be activated via thrombin
and thromboxane A2 receptors in human platelet membranes
(19), suggesting that both G-proteins are involved in the acti-
vation of platelets. Interestingly, both receptors as shown in
the present study induce phosphorylation of both G-protein
a-subunits in intact human platelets. Both receptors also acti-
vate Gq family members leading to the activation of PLCb and
the subsequent rise in [Ca21]i and PKC activation. Thus, it is
possible that thrombin and thromboxane A2 induced Ga12/13
FIG. 6. Basal and PMA stimulated activity of different PKC
isoforms expressed in COS-7 cells. COS-7 cells were transfected
with cDNAs encoding the indicated isoforms of PKC. After 45 h, cells
were then incubated in the absence or presence of 100 nM PMA, and
PKC activity was determined as described under “Experimental Proce-
dures.” Shown are mean values 6 S.D.
FIG. 7. PMA induced phosphorylation of Ga12 and Ga13 in
COS-7 cells expressing different PKC isoforms and Ga12 or Ga13.
COS-7 cells were cotransfected with cDNAs encoding the indicated
isoforms of PKC and cDNAs encoding Ga12 (panels A and B) or Ga13
(panel C and D). The total amount of DNA was maintained constant by
adding DNA of a vector encoding b-galactosidase. Cells were then
incubated in the absence or presence of 500 nM PMA (PMA 2/1) for 5
min, and solubilized cells were incubated with the anti-Ga12 (panels A
and B) or the anti-Ga13 antiserum (panels C and D) as described.
Precipitated proteins were subjected to SDS-PAGE. Shown are autora-
diograms of SDS-polyacrylamide gels with the position of the 43-kDa
standard protein shown on the left.
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phosphorylation in platelets results from activation of PLCb by
Gaq representing “cross-talk” between the Gq/PLCb pathway
and G12/13. Constitutively active mutants of Ga12 and Ga13
were recently shown to stimulate stress fiber formation and
focal adhesion assembly through the small guanine nucleotide
binding protein Rho in Swiss 3T3 cells, whereas activated
forms of Gaq or Gai2 had no effect (18). Aggregation of platelets
in response to thrombin has been found to be inhibited by
Clostridium botulinum C3 exoenzym, which ADP-ribosylated
and inhibits Rho (32). Thus, mediating the activation of Rho in
platelets exposed to thrombin is a possible function of Ga12 and
Ga13. A striking feature of Ga12 and Ga13 studied in purified
form is their low rate of guanine nucleotide turnover (20, 21).
Similarly, both a-subunits showed a very slow rate of GTP
binding in platelet membranes; GTP binding stimulated
through the thromboxane A2 and thrombin receptor reached a
maximum only after 30 min (19). This guanine nucleotide ex-
change rate seems to be far to slow to allow Ga12 and Ga13 to
play a significant role during platelet activation which takes
place within a few minutes. There might be mechanisms lead-
ing to a faster activation of G12 and G13 which eluded experi-
mental analysis in cell free systems. It is tempting to speculate
that the rapid phosphorylation of Ga12 and Ga13 we observed in
activated platelets may be part of a mechanism which leads to
a faster activation of G12/13 and triggers or sustains their func-
tion in platelet activation.
Taken together, we provide evidence that Ga12 and Ga13 are
rapidly phosphorylated in activated platelets in a PKC-depend-
ent manner and that this in vivo phosphorylation can be re-
constituted in a cotransfected system. Once, the effector func-
tion directly regulated by G-proteins of the Ga12 family has
been characterized, the effect of PKC-mediated phosphoryla-
tion on G12/13 signaling can be determined.
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Note Added in Proof—Recently, Kozasa and Gilman (33) showed that
purified Ga12 can be phosphorylated by PKCa in vitro.
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